Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440942 · ClinicalTrials.gov registry record · Phase 1
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Peter Hosein, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05440942: Completed Phase 1 study, sponsored by Peter Hosein, MD.
NCT05440942 is a Phase 1 study that has completed, run by Peter Hosein, MD. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05440942, a Phase 1 study, has completed, sponsored by Peter Hosein, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Primary Outcome
The RP2D of combination therapy of trametinib, ruxolitinib and retifanlimab (TR\^2) therapy will be determined as the maximum tolerated dose of combination treatment (in mg) as assessed by treating physician using the NCI-CTCAE Version 5.0.
Interventions
- DRUG Retifanlimab
- DRUG Ruxolitinib
- DRUG Trametinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 1 |
What the finished NCT05440942 record still lists
NCT05440942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT05440942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05440942 about?
NCT05440942 is a clinical study titled "Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT05440942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-01-19. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05440942?
The interventions under investigation include: Retifanlimab (DRUG), Ruxolitinib (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT05440942?
This trial is sponsored by Peter Hosein, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05440942's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI